Empreses emergents
2002
ONE WAY LIVER SL (OWL) (Previously ONE WAY LIVER GENOMICS SL)Metabolòmica amb productes de diagnòstic pioners i serveis únics d'R+D per a la comunitat científica
Adreça
Parque Tecnológico de Bizkaia EDIFICIO 502, 48160, Espanya
Dades financeres
| Data | Inversors | Quantitat | Etapa | |
| Jan 2004 | 1 € | Early VC |
Resum financer
Encara no s'han registrat ingressos
Propietat CERCA
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
The activity of the company is centered in the area of health and its objective is to identify, validate, patent and commercialize early diagnostic and/or prognostic systems, as well as therapeutic targets of hepatic diseases and other great prevalence complex pathologies. To accomplish this we use, metabolomics and bioinformatics have established a complete and highly productive platform which supports the advance of our developments.
Business Lines
Metabolomics Services to external organizations: OWL offers metabolomic services to pharmaceutical and biotechnology companies in key areas such as biomarker discovery, clinical studies, companion diagnostics and toxicology.
Business Lines
Metabolomics Services to external organizations: OWL offers metabolomic services to pharmaceutical and biotechnology companies in key areas such as biomarker discovery, clinical studies, companion diagnostics and toxicology.
Descripció del producte
OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.
DIAGNOSTIC PRODUCTS:
"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.
R&D SERVICES:
OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.
DIAGNOSTIC PRODUCTS:
"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.
R&D SERVICES:
OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.
Empresa tancada o sortida